Long Chain Fatty Acid Uptake In Vivo: Comparison of [¹²⁵I]-BMIPP and [³H]-Bromopalmitate

Insulin resistance is characterized by increased metabolic uptake of fatty acids. Accordingly, techniques to examine in vivo shifts in fatty acid metabolism are of value in both clinical and experimental settings. Partially metabolizable long chain fatty acid (LCFA) tracers have been recently developed and employed for this purpose: [9,10-³H]-(R)-2-bromopalmitate ([³H]-BROMO) and [¹²⁵I]-15-(ρ-iodophenyl)-3-R,S-methylpentadecanoic acid ([¹²⁵I]-BMIPP). These analogues are taken up like native fatty acids, but once inside the cell do not directly enter β-oxidation. Rather, they become trapped in the slower processes of ω and α-oxidation. Study aims were to (1) simultaneously assess and compare [³H]-BROMO and [¹²⁵I]-BMIPP and (2) determine if tracer breakdown is affected by elevated metabolic demands. Catheters were implanted in a carotid artery and jugular vein of Sprague-Dawley rats. Following 5 days recovery, fasted animals (5 h) underwent a rest (n = 8) or exercise (n = 8) (0.6 mi/h) protocol. An instantaneous bolus containing both [³H]-BROMO and [¹²⁵I]-BMIPP was administered to determine LCFA uptake. No significant difference between [¹²⁵I]-BMIPP and [³H]-BROMO uptake was found in cardiac or skeletal muscle during rest or exercise. In liver, rates of uptake were more than doubled with [³H]-BROMO compared to [¹²⁵I]-BMIPP. Analysis of tracer conversion by TLC demonstrated no difference at rest. Exercise resulted in greater metabolism and excretion of tracers with ~37% and ~53% of [¹²⁵I]-BMIPP and [³H]-BROMO present in conversion products at 40 min. In conclusion, [³H]-BROMO and [¹²⁵I]-BMIPP are indistinguishable for the determination of tissue kinetics at rest in skeletal and cardiac muscle. Exercise preferentially exacerbates the breakdown of [³H]-BROMO, making [¹²⁵I]-BMIPP the analogue of choice for prolonged (>30 min) experimental protocols with elevated metabolic demands.